Equal lasting proof is made available by Giaccotto, by Santerre and by Vernon (2005), those the influence of the material drug prices on R& estimate; D-intensity. Since drug prices are connected directly with industrial incomes, offers of this study a similar illustration of the process, by which expenditure for research is decided. Report of these authors „a 10% ascent in the growth of the material drug prices is with one nearly 6% increase of the growth of R& connected; D-intensity “(P. 204-205). Which both suggest these studies, an investment model is not at all, but rather one, which specifically uses existing internally produced capital for the development purposes. Where uncertainty levels are high, this process has the advantage of the warranty that all existing capital for research purposes is used. Which it still it does not show does so could, more iswhether, which this distribution process leads to an abundance or an insufficient spendingonpharmaceutical research. Whatwe observe are that expenditure increased strongly in the last decades. Newresources flowed into the process, by which new drugs are not discovered and it announcements give that many promising avenues of the research are neglected. Onthis point, Grabowski andVernon (1990, 1994) estimation efficiency factors of the investment in the pharmaceutical research and development and report evaluates somewhat more highly than the connected costs of the procurement of capital. In their last study they close: „the estimated central return to new introduction of the chemical nature of pharmaceutical industry (NCE) for the first half of the eighties-years was 11,1% compared to the estimated (material) costs of the procurement of capital of 10.5% during the same period “(P. 404). This, which also finds, suggests finding that one is improbable, unausgenutzte main opportunities. Still without determining a social optimum, one cannot form firm summaries over the sufficiency of the operational funds, which are directed toward these activities. On the question of the technical efficiency, results are also mixed. The productivity the pharmaceutical research capital, withdrew sharply in the last years, at least if it is measured by the number of new chemical natures, introduced; and the costs of the discovery and the Entwickelns of these products increased according to itself. The promise one science based research process led not to the larger efficiency, which was project engineering by its early applicants. Cockburn, Henderson and star (1999) emphasize the value of the organizational factors and the distribution of power relationshipswithin firmfor the speed, at which new research methods are used. Some enterprises to the new technology than others are corresponded to more. The authors notice that all emphasized their correspondents „that differences concerning the historical experience of the enterprise, in their `knowledge capital, ' were critically important, if one formed the assumption decision “(P. 19). In order to examine the diffusion process empirically, Cockburn investigate et al. the relationship between patenting and publishing by the scientific personnel of the company. As the older, empirischeren beginnings, were valid these activities replacement were used, and than the publication not the lively research discoveries. In contrast to this research organizations saw the publication of the research discoveries using science based the methods differently than. These activities became lively as promotion of the increased interdependence with the scientific community. For this reason patenting and | There cannot be a question, which was somewhat very wonderful, exciting, extremely importantly and productive research and within pharmaceutical industry is done. However think I not that she would do this fine abort in each regard and the worthwhile activities to underline to that much, which research in pharmaceutical industry is called little relationship too, which most people engaged themselves in the Academic and research work to regard, around scientific research.2 be does not have, if this illustration applied to the early postwar years, it the pharmaceutical researchprocess very well at the beginning 21. Century describes. Which once was, a largely empirical discovery process has itself entwickeltWhere uncertainty levels of acres high, this process has the advantage OF ensuring that all available of find of acres used for research PUR-pos. What it does emergency demonstrate, nor could it DO so, more iswhether this allocation process leads tons on excess or insufficient spendingonpharmaceutical research. Whatwe observe is that spending has increased strongly in recent decades. Newresources have flowed into the process by which new drugs acres discovered, and there acres NO indications that promising avenues OF research acres neglected. Onthis POINT, Grabowski andVernon (1990, 1994) estimate of advice OF return from investment in pharmaceutical research and development, and report VALUEs slightly more higher than the associated cost OF capital. Into their more latter study they conclude: “the estimated mean return on pharmaceutical industry new chemical entity (NCE) introductions for the roofridge helped OF the 1980s which 11,1% compared with the estimated (material) cost OF capital OF 10,5% more over the same by iodine” (p. 404). This finding thus suggests that one is unlikely tons finds to major unexploited opportunities. Determining A social optimum, one CAN emergency make firm conclusions about quietly, without the sufficiency OF of resources directed toward thesis of activities. Onthe question OF technical efficiency, results acres thus mixed. The productivity OF pharmaceutical research find has receded sharply in recent years, RK leases when measured by the NUMBERs OF of new chemical entities introduced; and the cost OF discovering and developing thesis products has correspondingly increased. The promise OF A science based research process has emergency LED ton the more greater efficiency that which projected by its early proponents. Cockburn, Henderson, and star (1999) emphasize the importance OF organizational factors and the distribution OF power relationshipswithin the firmfor the speed RK which new research methods acres employed. Some firms acres more suited ton the new technology than others. The authors note that all their informant emphasized “that differences into the historical experience OF the firm, into their `knowledge capital, 'were critically important into shaping the adoption decision” (p. 19). Ton examine the diffusion process empirically, Cockburn et al. explore the relationship between patenting and publishing by the company's scientific staff. When the more older, more empirical approaches were employed, thesis of activities were considered substitutes, and the publication OF research findings emergency encouraged. In contrast, research organizations using more science based methods saw the publication OF research findings differently. Thesis activities were encouraged as promoting increased interdependence with the scientific community. For this reason, patenting and | There CAN fuel element NO question that some very wonderful, exciting, extremely important, and productive research has been and is being done within the pharmaceutical industry. However, I DO emergency think that it would detract in any way from thesis fine and worthwhile activities ton of POINT out that much that is called research into the pharmaceutical industry has little relationship tons what most people engaged in academic and research activities would consider tons of fuel element scientific research.2 If this picture applied ton the early was years, it does emergency describe the pharmaceutical researchprocess verywell RK the beginning OF the twenty roofridge century. What which once A largely empirical discovery process has developed